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System of adverse drug reactions reporting: What, where, how, and whom to report?
Sir, The continuous progress in medical and pharmaceutical sciences has made the availability of pharmaceutical products in the Indian market to prevent and control of several disease conditions. Irrespective of the benefi ts associated with the use of medicines adverse effects associated with them has emerged the challenges of monitoring Adverse Drug Reactions (ADRs) over large population base. World Health Organization (WHO) defined ADR as "A response which is noxious and unintended, and which occurs at doses normally used in humans for the prophylaxis, diagnosis, or therapy of disease, or for the modification of physiological function." [1] To improve public health, the safe use of medicine must be monitored through an effective pharmacovigilance (PV) system. PV is defined as the science and activities relating to the detection, assessment, understanding and prevention of adverse effects, or any other possible drug-related problems. [2] Indian Pharmacopoeia Commission (IPC), Ghaziabad is functioning as a National Coordination Centre (NCC) for Pharmacovigilance Programme of India (PvPI). One Hundred and fi fty ADR monitoring centres (AMCs) were established in various medical institutions/hospitals across India to monitor and collect ADR reports under NCC-PvPI. [3] 
What to Report
PvPI encourages all types of suspected ADRs reporting whether they are known, unknown, serious, or nonserious, frequent, or rare regardless of an established causal relationship between a drug and the reaction. ADRs related with the use of allopathic medicines, vaccines, traditional medicines, medical devices, contrast media, etc., can be reported. 
Where to Report
All healthcare professionals (clinicians, dentists, pharmacists, nurses) and patient/consumers can report ADRs to NCC or AMCs. The pharmaceutical companies can also send individual case safety reports for their product to NCC.
How to Report
Suspected ADR reporting forms [ Figure 1 ] for healthcare professionals and consumers are available on the website of IPC to report ADR. To remove language barrier in ADR reporting, the consumer reporting form [ Figure 2 ] are made available in 10 vernacular languages (Hindi, Tamil, Telugu, Kannada, Bengali, Gujarati, Assamese, Marathi, Oriya, and Malayalam). ADRs can be also reported via PvPI helpline number (18001803024) on weekdays from 9:00 am to 5:30 pm. [3] The mobile Android application for ADR reporting has also been made available to the public.
Whom to Report
A reporter can send fi lled ADR reporting form directly to NCC or their nearest AMC. In case of AMC, these reports are confi rmed by healthcare professionals and entered into Vigiflow and sent to NCC for further assessment. [4] These reports are then fi nally reviewed at NCC and committed to WHO-Uppsala Monitoring Centre. The obtained information is entered in the drug safety database, analyzed, and assessed by the experts to identify new signals. [5] The submitted ADR report does not have any legal implication on the reporters. The patients' identity are held in strict confi dence and protected to the fullest extent.
Therefore, healthcare providers are encouraged to report ADRs for better understanding of the risk associated with the use of medicines and to safeguard the health of Indian population.
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Factors for early death in rabies-the bitter truth
Sir, Early death phenomenon in rabies reported by Sadeghi et al. [1] is informative and has long been recognized in patients whose incubation period is shorter than average in patients who were inadequately vaccinated with or without accompanying immunoglobulin and develop rabies. [2] However, we would like to recall other factors related to virus, patients, therapeutic agents, and care providers contributing to early death, so as to introduce appropriate measures to ensure quality in service and enforce patient safety.
The high viral load inoculated at the site of bite, which infects motor endplates and motor axons without previous replication in the muscle and its virulence. Those related to patients are anatomical site of bite such as head and neck, [3] or bite in highly innervated areas such as fingers as noted in this case, [1] which has close proximity to central nervous system, and nonfeasibility to infi ltrate adequate dose of human rabies immunoglobulin (HRIG). Next is the functional status of the immune system, which may be immune enhancement or "early death" phenomenon through B cells during the incubation period, and/ or nonspecifi c immunosuppressive effect following rabies infection. Rabies nucleoprotein acts as a weak superantigen, and directly induces proliferation of human CD4 Th2 cells bearing the V8 TCR, which suppresses the immunity through polyclonal antibody response. [4] Matters related to therapeutic agents are questionable status of the potency of vaccine and HRIG, due to inherent technical constraints and electricity problems in countries such as India. Certain important factors related to health care providers are nonadherence to World Health Organization (WHO) postexposure prophylaxis protocol. Furthermore, health care providers should avoid prescribing antimalarials and other drugs that interfere with the effectiveness of rabies vaccine or HRIG.
To overcome these, we need identifi cation of other responsible factors so as to empower the health care providers for effective services and community health education. [5] Our motto shall be "no death due to rabies" through community education, early intervention, quality assurance of therapeutic agents, and adherence to WHO protocol.
